Showing results (81-90 of 493) with videos related to
Sort By:
Pageof 50
Neuropsychopharmacology Reports|September 9, 2020
Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in JapanTaro Kishi, Reiji Yoshimura, Kenji Sakuma, et al.Neuropsychopharmacology Reports|June 26, 2025
Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta-AnalysisYasufumi Nishii, Kenji Sakuma, Shun Hamanaka, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 29, 2026
Relapse and its modifiers after antipsychotic discontinuation in first-episode non-affective psychosis: A systematic review and meta-analysisTaro Kishi, Leslie Citrome, Kenji Sakuma, et al.Psychopharmacology|February 1, 2020
Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysisTaro Kishi, Toshikazu Ikuta, Yuki Matsuda, et al.Journal of Psychiatric Research|August 27, 2020
Factors associated with discontinuation in the drug and placebo groups of trials of second generation antipsychotics for acute schizophrenia: A meta-regression analysis: Discontinuation in antipsychotic trialsTaro Kishi, Yuki Matsuda, Kenji Sakuma, et al.Fujita Medical Journal|May 1, 2025
Association between eveningness and depressive symptoms in daytime workers: A cross-sectional analysis of the Aichi Workers' Cohort StudyKazuhito Ishihara, Tsuyoshi Kitajima, Atsuhiko Ota, et al.Neuropsychiatric Disease and Treatment|December 24, 2016
Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trialsYuji Okuyama, Kazuto Oya, Shinji Matsunaga, et al.Journal of Alzheimer'S Disease : JAD|January 13, 2016
Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson's Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative ModulatorsIchiro Yasue, Shinji Matsunaga, Taro Kishi, et al.European Archives of Psychiatry and Clinical Neuroscience|August 26, 2015
Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trialsKazuto Oya, Yuki Matsuda, Shinji Matsunaga, et al.Neuropsychopharmacology Reports|July 2, 2021
Outcomes of patients with schizophrenia who discontinued long-acting injectable antipsychotic therapy due to adverse events: A chart reviewTaro Kishi, Kenji Sakuma, Makoto Okuya, et al.Pageof 50